Picton Mahoney Asset Management
AMLX icon

Picton Mahoney Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Picton Mahoney Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.39K Buy
+189
New +$2.92K ﹤0.01% 1275
2022
Q3 		– Sell
-23,200
Closed -$446K – 756
2022
Q2 		$446K Buy
+23,200
New +$275K 0.02% 584

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Picton Mahoney Asset Management's AMLX Position: Q2 2026 in Review

Picton Mahoney Asset Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 189 shares worth $3.39K. The stake represents ﹤0.01% of the portfolio and ranks #1275 among its holdings. This is a return to the name: Picton Mahoney Asset Management previously reported a position in AMLX as recently as Q2 2022.

Picton Mahoney Asset Management first reported a position in AMLX in Q2 2022 and has held it in 2 quarters since. The position peaked at $446K in Q2 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Picton Mahoney Asset Management held 189 shares of Amylyx Pharmaceuticals worth $3.39K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Picton Mahoney Asset Management position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Picton Mahoney Asset Management's portfolio in Q2 2026, its #1275 holding.
  • Picton Mahoney Asset Management first reported a position in Amylyx Pharmaceuticals in Q2 2022 and has held it in 2 quarters since.
  • Picton Mahoney Asset Management's Amylyx Pharmaceuticals position peaked at $446K in Q2 2022.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.